Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 10 Oct 2024
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Carfilzomib (Primary) ; Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary) ; Linvoseltamab (Primary) ; Nirogacestat (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 29 May 2024 Planned End Date changed from 7 Aug 2032 to 23 Jan 2033.
- 29 May 2024 Planned primary completion date changed from 13 Jan 2027 to 27 Mar 2027.
- 02 Nov 2023 According to a SpringWorks Therapeutics media release, In September 2023, first patient dosed in Regeneron-sponsored Phase 1b study arm evaluating nirogacestat in combination with linvoseltamab in patients with multiple myeloma.